Clinical Trial Highlights
TAVR is Noninferior to Surgical AVR in High-Risk Patients with Aortic Stenosis:
Results from the PARTNER Trial
Peer-reviewed Article I Summary Slides I Lecture Notes I
Results from the Randomized PARTNER Trial (Cohort B)
Peer-reviewed Article I Summary Slides I Lecture Notes I
One-Year Data from the RESOLUTE US Trial
Peer-reviewed Article I Summary Slides I Lecture Notes I
The PLATINUM Trial: New Metal Alloy DES is Similar to a Predicate DES for Uncomplicated Elective PCI
Peer-reviewed Article I Summary Slides I Lecture Notes I
The RAPS Trial: Radial Artery Grafts are Associated with Greater Longer-Term Patency than SVGs
Peer-reviewed Article I Summary Slides I Lecture Notes I
Radial Access is Not Superior to Femoral Access for Coronary Angiography or Intervention in Patients with ACS
Peer-reviewed Article I Summary Slides I Lecture Notes I
EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair Between Years 1 and 2
Peer-reviewed Article I Summary Slides I Lecture Notes I
Targeted LV Lead Placement Is Feasible and Associated With Enhanced CRT Response
Peer-reviewed Article I Summary Slides I Lecture Notes I
Comparison of 6 and 12 Months of DAT after Implantation of a DES
Peer-reviewed Article I Summary Slides I Lecture Notes I
No Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial
Peer-reviewed Article I Summary Slides I Lecture Notes I
Myocardial Viability Does Not Predict Survival Benefit After CABG
Peer-reviewed Article I Summary Slides I Lecture Notes I
DES Reduce the Need for Repeat Revascularization: Results from the ISAR-CABG Trial
Peer-reviewed Article I Summary Slides I Lecture Notes I
Preventing Contrast-Induced Acute Kidney Injury: Results from the REMEDIAL Trial ll
 |
Official Peer-Reviewed Highlights from the |
ACC.11
60th Annual Scientific Session and i2 Summit 2011
Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?
Since its approval in 1997, clopidogrel has been a cornerstone of therapy in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI) to reduce future ischemic events. Although the drug has led to significantly better outcomes, high variability in the antiplatelet effect has been demonstrated. A number of factors are responsible for this variability as demonstrated through pharmacodynamic and pharmacokinetic studies, including clinical factors and the presence of CYP2C19 loss-of-function alleles and reduced metabolism of clopidogrel to its active metabolite leading to attenuation of the intended anti-platelet effect [Brandt JT et al. J Thromb Haemost 2007]. See summary: Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?